Table 2.
Demographics and baseline characteristics in the safety population
| Characteristic | Dose escalation (n = 25) |
Dose expansion (n = 18) |
|---|---|---|
| Median age, years (range) | 62 (29‒81) | 57 (47‒71) |
| Median body weight, kg (range) | 75 (44‒119)a | 71 (55‒140) |
| Sex, n (%) | ||
| Female | 12 (48) | 15 (83) |
| Tumor type, n (%) | ||
| Colorectal cancerb | 10 (40) | 3 (17) |
| Breast cancer | 1 (4) | 8 (44) |
| Ovarian cancerc | 1 (4) | 4 (22) |
| Lung cancer | 3 (12) | 1 (6) |
| Bladder cancer | 0 | 1 (6) |
| Melanoma | 2 (8) | 0 |
| Squamous cell carcinomad | 2 (8) | 0 |
| Pancreatic cancer | 1 (4) | 0 |
| Esophageal cancer | 1 (4) | 0 |
| Mucoepidermoid carcinomae | 1 (4) | 0 |
| Peritoneal cancer | 1 (4) | 0 |
| Prostate cancer | 1 (4) | 0 |
| Thymic carcinoma | 1 (4) | 0 |
| Urethra carcinoma | 0 | 1 (6) |
an = 24
bColorectal cancer includes colon, colorectal, rectal, and cecum cancers
cOvarian cancer includes ovarian, fallopian tube, and peritoneal cancers
dLeft hip (n = 1), site not specified (n = 1)
ePrimary site not specified